Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia

Renan P. Souza, Gary Remington, Herbert Y. Meltzer, Jeffrey A. Lieberman, James L. Kennedy, Albert H C Wong

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Phosphodiesterase 4B (PDE4B) has been evaluated as a genetic risk factor for schizophrenia. Selective PDE4 inhibitor drugs have antipsychotic-like effects and reduce tardive dyskinesia-like movements in animal models. We investigated whether PDE4B genetic variants are associated with antipsychotic-induced tardive dyskinesia incidence and severity in schizophrenia patients. Our sample consisted of 169 Caucasian patients taking typical antipsychotic medication for at least 1 year. We found two PDE4B gene variants to be nominally associated with tardive dyskinesia (rs1338719 and rs7528545) in the overall population and two other variants nominally associated with the presence of tardive dyskinesia and severity in female patients (rs1890196 and rs783036). None of these results survived correction for multiple testing. Overall, our results do not support a genetic association between tardive dyskinesia and PDE4B.

Original languageEnglish (US)
Pages (from-to)264-269
Number of pages6
JournalInternational Clinical Psychopharmacology
Volume25
Issue number5
DOIs
StatePublished - Sep 2010

Keywords

  • Abnormal Involuntary Movement Scale
  • extrapyramidal symptoms
  • movement disorders
  • pharmacogenomics
  • rolipram

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia'. Together they form a unique fingerprint.

Cite this